Home » News » Biotech

Biotech

AFR Article on how CSL priced the world’s most expensive drug

December 8th, 2022

CSL is one of Australia’s greatest business and technical success stories and its shares have provided one of the best returns on the ASX among listed companies over the past decade. CSL has also been a very strong advocate of the R&D Tax Incentive and lobbied for maintenance of a strong and stable incentive to encourage local investment in R&D. A recent article in the Australian Financial review has detailed the process around receipt of US regulatory approval for the […]

Read More

International and Domestic Uptake of Medtech R&D

October 21st, 2022

Australia’s medical technology industry has experienced significant growth over the past few years, with industry experts saying healthcare is a major area for digital disruption. In 2021, the medtech industry was investing $10 billion a year in Australia, up from around $300 billion in 2013, according to the New Daily. Whatsmore, 15 of the top 20 biotech companies have sales and revenue, which wasn’t the case 15 years ago. Whether the demand has been a long time coming with an […]

Read More

Australian based Immutep Ltd receives $2.693M AUD R&D Tax Refund from French Government

September 26th, 2022

ASX Listed, Sydney based company Immutep Ltd (ASX:IMM) has recently announced on 23 September 2022 that it has received a €1,804,341 (around A$2,693,000) payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). A similar magnitude payment was received in the previous years. The payment relates to activity the company is conducting in Paris to develop its novel Immunotherapy treatments. Immutep Ltd also registers activities under the Australian R&D Tax Incentive. Whilst there is likely to […]

Read More

Telix Pharmaceuticals becomes Australian Biotech Success Story after being one of largest Refundable R&D Tax Offset Recipients

August 15th, 2022

Melbourne-based Telix Pharmaceuticals has been one of the largest recipients of the R&D Tax incentive, and has now achieved a rare feat in Biotechnology;  commercialising a product, and continuing to grow. The company reportedly received a more than $12M R&D tax offset refund for activity undertaken during the year ended 31 December 2020, and more than $11M in the preceding period, for their work on cancer diagnostic and treatment. Telix Pharmaceuticals’ technology uses radio pharmaceuticals to travel through the blood […]

Read More

Categories

Archives